Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 6;7(5):fcaf381.
doi: 10.1093/braincomms/fcaf381. eCollection 2025.

Machine learning integration of MRI and gait reveals mobility phenotypes in multiple sclerosis

Affiliations

Machine learning integration of MRI and gait reveals mobility phenotypes in multiple sclerosis

Hernan Inojosa et al. Brain Commun. .

Abstract

Mobility impairment is a hallmark of disease worsening in multiple sclerosis (MS), yet its phenotypic diversity and pathophysiology mechanisms are not completely understood. Conventional gait assessments often rely on subjective clinical measures, which may not fully capture the complexity of gait abnormalities. The integration of advanced quantitative gait analysis, quantitative from MRI, and machine learning (ML) may reveal unique mobility phenotypes, potentially reflecting underlying disease mechanisms and heterogeneity. In this study, we aimed to identify and characterize mobility phenotypes among people with MS (pwMS) using a mixed approach with spatiotemporal gait parameters and MRI-derived features, supported by unsupervised ML clustering. 1026 pwMS underwent comprehensive gait assessments and quantitative MRI between 2018 and 2023. Principal component analysis was applied for dimensionality reduction and k-means clustering to identify distinct phenotypes. Clusters were compared using demographic, clinical, and MRI features, with statistical comparisons performed using Kruskal-Wallis and Chi-square tests. Four gait clusters were identified. Cluster 1 (faster stable, 47.8%), demonstrated the most efficient gait features and highest grey matter fractions. Cluster 4 (slow severely unstable, 7.4%) showed profound disability, shortest strides, lowest velocity, and greatest variability. Intermediate clusters 2 (slower stable, 32.3%) and 3 (moderately unstable, 12.6%) had similar velocity but differed in cadence and stride length. Cluster 3, marked by shorter steps and increased cadence, showed higher lesion burden and lower brain parenchymal fraction, suggesting emerging structural impairment and possible compensatory gait. Clinical measures aligned with these findings: unstable Clusters 3 and 4 had the highest proportion of progressive MS, worst disability scores, longest disease duration, and greatest self-reported gait impairment. Integrating quantitative MRI metrics with spatiotemporal gait analysis has the potential to phenotype clinical impairments in pwMS. ML-driven analysis identified a novel intermediate cluster, distinguished by a gait with increased cadence and shorter strides, alongside distinct MRI abnormalities. This pattern may reflect a potential adaptation within the mobility spectrum, not yet conclusively discernible by human raters but detectable through ML.

Keywords: mobility phenotyping; multimodal analysis; multiple sclerosis; quantitative MRI; unsupervised clustering.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. HI received speaker honoraria from Roche and financial support for research activities from Novartis, Teva, Neuraxpharm, Biogen and Alexion. K.A. received personal compensation from Novartis, Biogen Idec, Teva, Sanofi and Roche for consulting services. T.Z. reports scientific advisory board and/or consulting for Biogen, Roche, Novartis, Celgene and Merck; compensation for serving on speakers bureaus for Roche, Novartis, Merck, Neuraxpharm, Sanofi, Celgene and Biogen; and research support from Biogen, Novartis, Merck and Sanofi.

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
PCA loadings of gait and MRI metrics. The heatmap illustrates the absolute PCA loading values of each standardized gait and MRI variables on the first three PCs derived from the dataset (N = 1026). Higher absolute values indicate stronger contribution to each component. Variability (Var) measures derive from SD assessment. Gait parameters (e.g. velocity, cadence) exhibit higher loadings in PC1. MRI features, including BPF and T2 lesion volume, contribute mainly to PC2. PC3 predominantly captures structural brain changes, with higher contributions from grey parenchymal fraction and white matter fractions. Diff: difference; T25FWT, timed 25-foot walk test; Vol, volume; Infr, infratentorial.
Figure 2
Figure 2
K-means clusters based on PCA components. Results of K-means clustering applied to the first three PCs derived from gait and MRI-based features (N = 1026). The top panel (A) shows 2D scatter plots of the clusters across different PCs combinations (PC1 vs. PC2, PC1 vs. PC3 and PC2 vs. PC3, respectively). The bottom panel (B) provides a 3D visualization of the clusters, with colour-coding representing different cluster assignments. The silhouette score (0.294), Calinski–Harabasz score (507.979) and Davies–Bouldin score (1.094) indicate the clustering validity and separability. Purple: Cluster 1 (faster stable gait, n = 490). Green: Cluster 2 (slower stable gait, n = 331). Blue: Cluster 3 (moderately unstable gait, n = 129). Yellow: Cluster 4 (slow severely unstable gait, n = 76).

References

    1. Cameron MH, Wagner JM. Gait abnormalities in multiple sclerosis: Pathogenesis, evaluation, and advances in treatment. Curr Neurol Neurosci Rep. 2011;11(5):507–515. - PubMed
    1. Kister I, Chamot E, Salter AR, Cutter GR, Bacon TE, Herbert J. Disability in multiple sclerosis: A reference for patients and clinicians. Neurology. 2013;80(11):1018–1024. - PMC - PubMed
    1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169–180. - PMC - PubMed
    1. Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers. 2013;35(6):687–699. - PMC - PubMed
    1. Takla TN, Feldpausch J, Edwards EM, et al. Cerebellar volume measures differentiate multiple sclerosis fallers from non-fallers. Brain Sci. 2025;15(1):77. - PMC - PubMed

LinkOut - more resources